PBYI Surges 30% in 3 Months: A Look at Nerlynx Sales and Pipeline Prospects

Puma Biotechnology's (PBYI) shares have surged 29.6% in three months, outperforming the industry's 3.9% rise. The stock's growth is driven by better-than-expected results and improving sales of its sole marketed product, Nerlynx. Nerlynx sales have risen 9% YoY to $92.3 million in the first six months of 2025, and the company expects continued demand-driven growth. PBYI is also developing alisertib, a promising pipeline candidate for hormone receptor-positive breast cancer and SCLC.

Puma Biotechnology's (PBYI) shares have surged by 29.6% over the past three months, significantly outperforming the industry's 3.9% rise. The stock's impressive growth can be attributed to better-than-expected financial results and the company's improving sales of its sole marketed product, Nerlynx. Nerlynx sales have increased by 9% year-over-year (YoY) to $92.3 million in the first six months of 2025, reflecting strong demand-driven growth.

PBYI's success is also driven by its promising pipeline candidate, alisertib, which is under development for hormone receptor-positive breast cancer and small cell lung cancer (SCLC). The company's focus on these high-potential markets underscores its strategic approach to growth and innovation.

In addition to its current products and pipeline, PBYI's debt-free financial position provides a solid foundation for future investments and expansion. The company's strong financial health, coupled with its commitment to developing innovative therapies, positions it as a notable player in the biotechnology sector.